Other News To Note
Wednesday, July 18, 2012
Ipsen SA, of Paris, said partner Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., was notified that the FDA placed on hold both Phase III studies evaluating IB1001, an intravenous recombinant Factor IX therapy for the treatment and prevention of bleeding episodes in people with hemophilia B.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.